Training future cancer treatment providers in immune therapies
Cancer Immunotherapy and Experimental Therapeutics - T32
['FUNDING_TRAINING'] · UNIVERSITY OF COLORADO DENVER · NIH-10646231
This study is all about helping future doctors and researchers learn how to use new immune-based treatments for cancer, so they can better understand how these therapies work and help patients manage any side effects.
Quick facts
| Phase | ['FUNDING_TRAINING'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF COLORADO DENVER (nih funded) |
| Locations | 1 site (Aurora, UNITED STATES) |
| Trial ID | NIH-10646231 on ClinicalTrials.gov |
What this research studies
This research program focuses on training the next generation of oncology clinicians and researchers in advanced immune-directed cancer therapies. It aims to equip them with the necessary skills to navigate the rapidly evolving landscape of cancer treatment, which increasingly relies on understanding the immune system's role in fighting cancer. Participants will learn about new therapeutic agents, their mechanisms of action, and how to manage unique side effects associated with these treatments. The program also emphasizes the development of strategies to optimize the use of immune-based therapies for cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with various types of cancer who may benefit from innovative immune-based therapies.
Not a fit: Patients who are not diagnosed with cancer or those who have exhausted all treatment options may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized cancer treatments that harness the power of the immune system.
How similar studies have performed: Previous research in immune-directed therapies has shown promising results, indicating that this approach has the potential to significantly improve cancer treatment outcomes.
Where this research is happening
Aurora, UNITED STATES
- UNIVERSITY OF COLORADO DENVER — Aurora, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JIMENO, ANTONIO — UNIVERSITY OF COLORADO DENVER
- Study coordinator: JIMENO, ANTONIO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anticancer immunotherapy, immune-based cancer therapies, immunotherapy for cancer, immunotherapy of cancer